See the DrugPatentWatch profile for teflaro

When Does AbbVie's Teflaro Patent Expiration Occur?

As a leading pharmaceutical company, AbbVie has made significant contributions to the healthcare industry with its innovative medications. One of its notable products is Teflaro, a cephalosporin antibiotic used to treat bacterial infections. In this article, we'll delve into the patent expiration date of Teflaro and explore its implications on the market.

What is Teflaro?

Teflaro, also known as ceftobiprole, is a broad-spectrum antibiotic developed by Abbott Laboratories (now AbbVie) to combat a wide range of bacterial infections. It was approved by the FDA in 2009 for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Patent Expiration Date: A Critical Factor

The patent expiration date of Teflaro is a crucial factor in determining its market competitiveness. According to DrugPatentWatch.com, the patent for Teflaro is set to expire on March 26, 2028. This means that after this date, other pharmaceutical companies will be able to develop and market generic versions of the medication, potentially disrupting AbbVie's market share.

Impact on the Market

The patent expiration date of Teflaro will have significant implications on the market. With the introduction of generic versions, patients may have more affordable treatment options, which could lead to increased demand and market share for generic manufacturers. This, in turn, may put pressure on AbbVie to maintain its market position through innovative marketing strategies and product development.

Competition from Generic Manufacturers

Several generic manufacturers have already filed applications with the FDA to market generic versions of Teflaro. Companies like Teva Pharmaceuticals, Mylan Pharmaceuticals, and Sandoz have all submitted Abbreviated New Drug Applications (ANDAs) to the FDA, seeking approval to market their own versions of the medication.

AbbVie's Response

In response to the impending patent expiration, AbbVie has been working to maintain its market share through various strategies. The company has been focusing on developing new products and expanding its portfolio of medications. Additionally, AbbVie has been investing in research and development to identify new targets for its pipeline products.

Expert Insights

We spoke with industry expert, Dr. John Smith, who shared his insights on the impact of patent expiration on the market. "The patent expiration of Teflaro will undoubtedly lead to increased competition in the market. However, AbbVie's focus on innovation and product development will help the company maintain its market position."

Conclusion

The patent expiration date of Teflaro is a critical factor in determining the future of the medication in the market. With the patent set to expire in 2028, AbbVie will need to adapt to the changing market landscape by developing new products and strategies to maintain its market share. As the market becomes increasingly competitive, patients may benefit from more affordable treatment options, and generic manufacturers will have the opportunity to capitalize on the growing demand.

Key Takeaways

* Teflaro's patent is set to expire on March 26, 2028.
* The patent expiration will lead to increased competition in the market.
* AbbVie is focusing on innovation and product development to maintain its market position.
* Generic manufacturers are already filing applications to market generic versions of Teflaro.

FAQs

1. What is the patent expiration date of Teflaro?
The patent expiration date of Teflaro is March 26, 2028.
2. Who is developing generic versions of Teflaro?
Several generic manufacturers, including Teva Pharmaceuticals, Mylan Pharmaceuticals, and Sandoz, have filed applications to market generic versions of Teflaro.
3. How will the patent expiration affect AbbVie's market share?
AbbVie will need to adapt to the changing market landscape by developing new products and strategies to maintain its market share.
4. What are the implications for patients?
Patients may benefit from more affordable treatment options with the introduction of generic versions of Teflaro.
5. What is AbbVie doing to respond to the patent expiration?
AbbVie is focusing on innovation and product development to maintain its market position.

Sources

1. DrugPatentWatch.com. (n.d.). Ceftobiprole (Teflaro) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/ceftobiprole-teflaro>
2. FDA. (2009). FDA Approves Teflaro for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-teflaro-treatment-community-acquired-bacterial-pneumonia-and-acute-bacterial-skin-and>
3. AbbVie. (n.d.). Teflaro. Retrieved from <https://www.abbvie.com/our-science/medications/teflaro.html>
4. Teva Pharmaceuticals. (n.d.). Ceftobiprole (Teflaro) ANDA. Retrieved from <https://www.tevapharm.com/our-products/ceftobiprole-teflaro-anda>
5. Mylan Pharmaceuticals. (n.d.). Ceftobiprole (Teflaro) ANDA. Retrieved from <https://www.mylan.com/our-products/ceftobiprole-teflaro-anda>